Amneal Pharmaceuticals announced a definitive agreement to acquire Kashiv BioSciences, creating a fully integrated global biosimilars platform.
The transaction, pending shareholder and regulatory approvals, is expected to close in the second half of 2026.
Kashiv brings development and manufacturing expertise, while Amneal adds commercial scale and a portfolio of ~300 generic, specialty, and biosimilar medicines.
CEOs Dr. Sandeep Athalye and co‑founders Chirag and Chintu Patel highlighted accelerated pipeline growth and expanded patient access as strategic benefits.